Frank Malinoski

4.9k citations

50 papers · 3.8k indexed · 1 hit paper · h-index 23

Microbiology top 0.1%
- Bacterial Infections and Vaccines 7
Epidemiology top 0.5%
- Pneumonia and Respiratory Infections 22
- Respiratory viral infections research 16
- Pneumocystis jirovecii pneumonia detection and treatment 8
Infectious Diseases top 2%
- Viral gastroenteritis research and epidemiology 5
- Viral Infections and Vectors 5
Otorhinolaryngology top 5%
Public Health, Environmental and Occupational Health top 5%
- Mosquito-borne diseases and control 11
Immunology
- Immunodeficiency and Autoimmune Disorders 8

Co-authors: Dace V. Madore Ih Chang Henry R. Shinefield Steven Black John Hansen George R. Siber Jill Hackell Wendy Watson
Cited by: Microbiology Epidemiology Infectious Diseases
Partner nations: United States Austria United Kingdom

In The Last Decade

Frank Malinoski

50 papers receiving 3.6k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2000 Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children

Peers

Countries citing papers authored by Frank Malinoski

Since Specialization

Citations

This map shows the geographic impact of Frank Malinoski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Malinoski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Malinoski more than expected).

Fields of papers citing papers by Frank Malinoski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Malinoski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Malinoski. The network helps show where Frank Malinoski may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Frank Malinoski, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Frank Malinoski Line = papers co-authored together Frank Malinoski links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: A phase 1 randomized controlled trial Dorota Borys,Richard Rupp,Ronald Smulders,Gurunadh R. Chichili,Laura Kovanda,Vicki Santos,Frank Malinoski,George R. Siber,Richard Malley,Shite Sebastian	2024	8
2	The nanomedicines alliance: an industry perspective on nanomedicines Frank Malinoski	2014	7
3	Parenteral Nutrition Prescribing Pattern Robin S. Turpin,Frank Xiaoqing Liu,Matt Prinz,Cynthia Macahilig,Frank Malinoski	2013	8
4	Development of a nanoparticle-based influenza vaccine using the PRINT® technology Ashley L. Galloway,Andrew Murphy,Joseph M. DeSimone,Jie Di,Jennifer Herrmann,Michael E. Hunter,Jeffrey P. Kindig,Frank Malinoski,Megan A. Rumley,Daria M. Stoltz,Thomas S. Templeman,Bolyn Hubby	2012	69
5	A Novel Active Respiratory Syncytial Virus Surveillance System in the United States Marnie L. Boron,Laurel Edelman,Jessie R. Groothuis,Frank Malinoski	2008	10
6	Correlation Between Respiratory Syncytial Virus (RSV) Test Data and Hospitalization of Children for RSV Lower Respiratory Tract Illness in Florida Michael J. Light,Jay H. Bauman,Kunjana Mavunda,Frank Malinoski,Mark Eggleston	2008	26
7	Respiratory Syncytial Virus: Seasonal Data for Regions of Florida and Implications for Palivizumab Jay H. Bauman,Mark Eggleston,Niki L. Oquist,Frank Malinoski	2007	13
8	Controlling invasive pneumococcal disease: is vaccination of at-risk groups sufficient? M A Fletcher,Dagna Laufer,E. David G. McIntosh,C Cimino,Frank Malinoski	2006	19
9	Post-marketing effectiveness of Prevnar [pneumococcal 7-valent conjugate vaccine (diphtheria CRM197 protein)] and implications for adult immunization Betsy Abraham-Van Parijs,Frank Malinoski	2003	4
10	Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine Steven Black,Henry R. Shinefield,John Hansen,Laura Elvin,Dagna Laufer,Frank Malinoski	2001	194
11	Efficacy, Safety, and Immunogenicity of Heptavalent Pneumococcal Conjugate Vaccine in Children Steven Black,Henry Shinefeld,MA Bruce Fireman,Mph Edwin Lewis,Mph Paula Ray,BA John R. Hansen,Laura Elvin,RN Kathy M. Ensor,Jill Hackell,George R. Siber,Frank Malinoski,Dace V. Madore,Ih Chang,Robert Kohberger,Wendy Wendy	2000	3
12	Vaccination of Seropositive Subjects with CHIRON CMV gB Subunit Vaccine Combined with MF59 Adjuvant for Production of CMV Immune Globulin Murray Drulak,Frank Malinoski,Steven A. Fuller,Solomon Stewart,S Hoskin,ANNE-MARIE DULIEGE,Rose E. Sekulovich,R.L. Burke,Scott Winston	2000	14
13	Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in childrenbreakdown → Steven Black,Henry R. Shinefield,Bruce Fireman,Edwin Lewis,Paula Ray,John Hansen,Laura Elvin,Kathleen Ensor,Jill Hackell,George R. Siber,Frank Malinoski,Dace V. Madore,Ih Chang,Robert Kohberger,Wendy Watson,Robert Austrian,Kathryn M. Edwards	2000	1817
14	Immunologic effects of anti-D (WinRho-SD) in children with immune thrombocytopenic purpura Sherri A. Zimmerman,Frank Malinoski,Russell E. Ware	1998	17
15	Immunologic effects of anti‐D (WinRho‐SD) in children with immune thrombocytopenic purpura Sherri A. Zimmerman,Frank Malinoski,Russell E. Ware	1998	1
16	Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children James C. King,Peter Vink,John Farley,MARIE PARKS,Martha Smilie,Dace V. Madore,Richard Lichenstein,Frank Malinoski	1996	69
17	SAFETY AND IMMUNOGENICITY OF 3 DOSES OF A 5-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV) IN HIV AND NON HIV-INFECTED CHILDREN < 2 YRS OF AGE.▴ 1037 James C. King,Peter Vink,John Farley,M. Guston Parks,Martha Smilie,DEBORAH A. HOGERMAN,Frank Malinoski	1996	1
18	Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis Pedro A. Piedra,SUSAN GRACE,Alan M. Jewell,Susan H. Spinelli,D. M. Bunting,DEBORAH A. HOGERMAN,Frank Malinoski,Peter Hiatt	1996	112
19	Strenuous exercise simulating hepatic injury during vaccine trials Frank Malinoski	1992	14
20	Prophylactic ribavirin treatment of dengue type 1 infection in rhesus monkeys Frank Malinoski,Sherman E. Hasty,Michael A. Ussery,Joel M. Dalrymple	1990	46

About Frank Malinoski

Frank Malinoski is a scholar working on Microbiology, Epidemiology and Virology, having authored 50 papers that have together received 3.8k indexed citations. Recurring topics across this work include Pneumonia and Respiratory Infections (22 papers), Respiratory viral infections research (16 papers), Mosquito-borne diseases and control (11 papers), Immunodeficiency and Autoimmune Disorders (8 papers), Pneumocystis jirovecii pneumonia detection and treatment (8 papers), Bacterial Infections and Vaccines (7 papers), Viral gastroenteritis research and epidemiology (5 papers) and Viral Infections and Vectors (5 papers). The work is most often cited by research in Microbiology (1.4k citations), Epidemiology (3.1k citations) and Infectious Diseases (645 citations). Frank Malinoski has collaborated with scholars based in United States, Austria and United Kingdom. Frequent co-authors include Dace V. Madore, Ih Chang, Henry R. Shinefield, Steven Black, John Hansen, George R. Siber, Jill Hackell, Wendy Watson, Kathryn M. Edwards and Robert Kohberger.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact